Patients with renal cell carcinoma (RCC) may exhibit renal impairment as a more or less direct consequence of their primary disease. Renal impairment may become a severe complication and alter the normal pharmacokinetic and pharmacodynamic behavior of treatment drugs, thus increasing the risk of side effects. We will discuss the cases of two advanced RCC patients with end-stage renal impairment submitted to dialysis who were treated with sorafenib tosylate in our center.
Our experience confirms the scarce literature data available so far that indicate that sorafenib can be used in patients undergoing dialysis. Dialysis cannot be considered per se a contraindication to sorafenib therapy, which can be effective. However, patients must be carefully selected and monitored, since sorafenib administration unquestionably increases the risk of side effects in patients affected by several conditions.
Van de Poll-FranseL.V., HoutermanS., Janssen-HeijnenM.L., DercksenM.W., CoeberghJ.W., HaakH.R.: Less aggressive treatment and worse overall survival in cancer patients with diabetes: a large population based analysis. Int J Cancer, 120: 1986–1992, 2007.
4.
NégrierS.: Role of arterial hypertension in kidney cancer. Progr Urol, 13(Suppl 2): 1197–1198, 2003.
5.
MaertensS., Van Den NoortgateN.J.: Kidney in old age. Acta Clin Belgica, 63: 8–15, 2008.
6.
FinkelK.W., ForingerJ.R.: Renal disease in patients with cancer. Nature Clin Pract Nephrol, 3: 669–678, 2007.
7.
MangoniA.A., JacksonH.D.: Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol, 57: 6–14, 2004.
8.
BuzioC., De PalmaG., PassalacquaR., PotenzoniD., FerrozziF., CattabianiM.A., VanentiL., BorghettiA.: Effectiveness of very low doses of immunotherapy in advanced renal cell cancer. Br J Cancer, 76: 541–544, 1997.
9.
StrumbergD., ClarkJ.W., AwadaA., MooreM.J., RichlyH., HendliszA., HirteH.W., EderJ.P., LenzH.J., SchwartzB.: Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist, 12: 426–437, 2007.
KaneR.C., FarrellA.T., SaberH., TangS., WilliamsG., LiangC., BoothB., ChidambaramN., MorseD., SridharaR., GarveyP., JusticeR., PazdurR.: Sorafenib for the treatment of advanced renal cell cancer. Clin Cancer Res, 12: 7271–7278, 2006.
12.
StrumbergD., RichlyH., HilgerR.A., SchleucherN., KorfeeS., TewesM., FaghihM., BrendelE., VoliotisD., HaaseC.G., SchwartzB., AwadaA., VoigtmannR., ScheulenM.E., SeeberS.: Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol, 23: 965–972, 2005.
13.
ClarkJ.W., EderJ.P., RyanD., LathiaC., LenzH.J.: Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res, 11: 5472–5480, 2005.
14.
MooreM., HirteH.W., SiuL., OzaA., HotteS.J., PetrenciucO., CihonF., LathiaC., SchwartzB.: Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol, 16: 1688–1694, 2006.
15.
SmithW., MarburyT., KipnesM., CihonF., LettieriJ., MazzuA.: Effects of renal impairment on the pharmacokinetics of sorafenib and its metabolites. AACR Annual Meeting, Los Angeles (USA), 934 (abstract), 2007.
16.
ParsaV.K.: Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. ASCO Genitourinary Cancers Symposium, Chicago (USA), 365 (abstract), 2008.
17.
GolshayanA.R., GeorgeS., ElsonP., WoodL., GarciaA., BukowskiR.M., RiniB.I.: VEGF-targeted therapy in metastatic renal cell carcinoma patients with renal insufficiency. ASCO Genitourinary Cancers Symposium, San Francisco (USA), 364 (abstract), 2008.
